Cepi Technical Resources Hub The cln has expanded in 2025 to 20 laboratories worldwide; the facilities will provide the same services to support vaccine development against one or more of cepi’s priority diseases – lassa virus, mers, nipah, and others. Cepi’s technical resources hub is an open access platform that aims to equip vaccine researchers, developers and funders with tools, methods, and knowledge to advance epidemic preparedness innovations.
Cepi Technical Resources Hub More information on processing of samples, shipment and data handling within the cepi centralized laboratory network can be found here. the testing service is free of charge, except for the shipment costs. to check your eligibility, complete the sample analysis request form. Driving consistency: cepi centralized laboratory network's conversion factor initiative for sars cov 2 clinical assays used for efficacy assessment of covid vaccines | human vaccines & immunotherapeutics volume 20 | 6 may 2024. Cepi's centralised laboratory network first opened to all covid 19 vaccine developers—both cepi funded and non cepi funded—free of charge (excluding sample shipping fees), in october 2020, for the analysis of covid 19 vaccine clinical trial samples up to phase iii studies. In order to monitor interest and adjust the testing capacity, we are requesting that all covid 19 vaccine developers interested in using cepi's centralised laboratory network complete this short survey.
Cepi Technical Resources Hub Cepi's centralised laboratory network first opened to all covid 19 vaccine developers—both cepi funded and non cepi funded—free of charge (excluding sample shipping fees), in october 2020, for the analysis of covid 19 vaccine clinical trial samples up to phase iii studies. In order to monitor interest and adjust the testing capacity, we are requesting that all covid 19 vaccine developers interested in using cepi's centralised laboratory network complete this short survey. After our significant contribution to controlling the sars cov 2 pandemic, the cln has expanded significantly, becoming the largest global network conducting global vaccine testing with 17 laboratories from 13 different countries announced so far. Cepi is working to galvanise the development of new vaccines and other biologic countermeasures against diseases that could cause the next devastating epidemic or pandemic. It aims to support cepi supported developers and others to evaluate cepi priority pathogen vaccines against common protocols to ensure alignment and information sharing when identifying the most promising candidates. Our network currently standardizes the assessment of vaccine efficacy against rare but potential diseases including lassa, nipah, monkeypox, sudan, marburg, mers, and others, ensuring uniformity and accelerating standardized assays for vaccines.
Cepi Technical Resources Hub After our significant contribution to controlling the sars cov 2 pandemic, the cln has expanded significantly, becoming the largest global network conducting global vaccine testing with 17 laboratories from 13 different countries announced so far. Cepi is working to galvanise the development of new vaccines and other biologic countermeasures against diseases that could cause the next devastating epidemic or pandemic. It aims to support cepi supported developers and others to evaluate cepi priority pathogen vaccines against common protocols to ensure alignment and information sharing when identifying the most promising candidates. Our network currently standardizes the assessment of vaccine efficacy against rare but potential diseases including lassa, nipah, monkeypox, sudan, marburg, mers, and others, ensuring uniformity and accelerating standardized assays for vaccines.
Comments are closed.